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Introduction
Bleeding is the most frequent complication of peptic
ulcer disease, occurring in 20% of patients with
ulcers1,2 and is a common cause of emergency hospital
admission. Despite the introduction of endoscopic
haemostatic methods and improvements in acid-
suppressive drugs, peptic ulcer bleeding remains a
life-threatening condition that carries a 5% to 10%
mortality rate.3-7
It is now well accepted that Helicobacter pylori is
the cause of type B gastritis and most peptic ulcers.
There is considerable evidence that eradication of
the organism markedly alters the natural history of
uncomplicated peptic ulcer disease and reduces the
recurrence of peptic ulceration.8-11 More information
on the relationship between H pylori and bleeding
peptic ulcers is now available.
The prevalence of H pylori infection
Helicobacter pylori has been detected in almost 100%
of patients with duodenal ulcers and in approximately
75% of those with gastric ulcers.12 The prevalence of
H pylori is, however, lower in patients with complicated
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peptic ulcer diseases. For example, in patients present-
ing with perforated peptic ulcer, the prevalence of
H pylori can be as low as 50%.13 Similarly, studies have
found that 70% to 85% of patients with bleeding peptic
ulcers have evidence of H pylori infection.14-16
The lower prevalence of H pylori in those with
bleeding peptic ulcers means that factors other than
H pylori are also important in the pathogenesis of
bleeding peptic ulcers. The use of non-steroidal anti-
inflammatory drugs (NSAIDs) is another important
factor in the development of bleeding peptic ulcers.
The use of NSAIDs has been found to be the most
common cause of duodenal and gastric ulceration
among patients who test negative for H pylori.17 Yet,
up to 10% of a series of patients with bleeding peptic
ulcers who were not NSAID users have been shown to
be free of H pylori infection.18
The lower prevalence of H pylori observed in patients
with bleeding peptic ulcers could also be due to the
varying sensitivity and specificity of the H pylori
diagnostic tests used in different studies. For example,
results from the urease test on antral biopsy samples
have been found to have a high false-negative rate for
H pylori in patients with bleeding duodenal ulcers.19,20
Interaction of H pylori and non-steroidal
anti-inflammatory drugs
Since both H pylori infection and the use of NSAIDs
are the most common causes of peptic ulceration, it
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is important to determine whether H pylori infection
increases the risk of peptic ulceration in patients who
are taking NSAIDs. Unfortunately, endoscopic and
epidemiological studies of patients with uncomplicated
peptic ulceration give conflicting results as to whether
or not H pylori infection increases the risk of ulcera-
tion in NSAID users. The results from studies of
patients with bleeding peptic ulcers are also conflict-
ing. Two case-control studies failed to demonstrate
any significant interaction between NSAIDs and
H pylori in bleeding peptic ulcers,21,22 while a third
case-control study concluded that H pylori infection
is associated with an increase in the risk for bleeding
peptic ulcers among NSAID users.23
In contrast, it is well known that a prior history of
ulcer disease is an important risk factor for the
development of ulcer complications in patients who
are taking NSAIDs24,25 and that these complications
develop within 1 month of commencing NSAID
therapy.26,27 These findings suggest that NSAIDs may
cause complications in ulcers that are present but
clinically silent. Patients who have H pylori–associated
ulcers thus seem to have a greater risk of developing
complicated ulcers during treatment with NSAIDs.
Diagnosing H pylori infection
Diagnostic tests to detect H pylori may be classified
as those that require endoscopic gastric mucosal
biopsies and those that do not require endoscopy and
hence are non-invasive. Biopsy-based tests include
gastric mucosal culture, histological examination, and
the rapid urease test (RUT). Non–biopsy-based tests
include the urea breath test and serological analysis.
Gastric mucosal culture remains the gold standard
for detecting H pylori and is particularly useful for
patients in whom eradication therapy has failed or
for participants of clinical trials in which antibiotic
resistance needs to be determined. However, culturing
for H pylori is generally not used for the diagnosis
of infection because of the lower sensitivity when com-
pared with other tests. In contrast, histological exami-
nation can detect gastritis as well as the presence of
H pylori, and the test generally has a good sensitivity
and specificity. Pitfalls that are related to sampling
error, observer error, staining methods, and density
of H pylori can occur, however.
The RUT is the most commonly used initial endo-
scopic test to diagnose H pylori infection owing to its
simplicity, accuracy, and relatively rapid results.
The RUT is based on the potent urease-producing
activity of H pylori; the results are thus available
within 1 to 24 hours. In contrast, the urea breath test
is a non-invasive, non-endoscopic test that also
employs the potent urease activity of the bacterium.
Patients are required to drink a solution of urea labelled
with carbon 13 or 14. Breath samples are collected
before and 30 minutes after the administration of the
labelled urea solution. The proportion of exhaled 13C
or 14C is then calculated. The sensitivity and specificity
of the urea breath test are very good. However, the
analysis of 13C levels requires an expensive mass
spectrometer, and 14C is radioactive and hence not
suitable for use in repeated examinations.
Serological analysis depends on the presence of
serum antibodies against H pylori. The test is not
usually used to diagnose infection with the bacterium
because the results may indicate a prior rather than a
current infection.
Since none of the above tests are perfect, it is
prudent to have two diagnostic tests performed to
confirm the presence of H pylori. This precaution is
particularly important when there are bleeding peptic
ulcers. Results from the RUT have been found to have
high false-negative rates in the presence of bleeding
duodenal ulcers,19,20,28,29 which may be related to
the presence of blood in the stomach. Biopsy-based
Table 1. H pylori infection and rebleeding in patients with and without eradication therapy
Study Study design Length of follow-up Ulcer type
(months)
Graham et al,34 1993 Non-randomised 12 GU‡/DU§
Labenz and Borsch,35 1994 Non-randomised 12 GU/DU
Jaspersen et al,36 1995 Randomised 12 DU
Rokkas et al,37 1995 Randomised 12 DU
Lai et al,38 1997 Randomised 53 DU
Macri et al,39 1998 Non-randomised 48 DU
* Rebleeding at the time of H pylori eradication therapy (No. of patients)†
 Rebleeding post-eradication (No. of patients)‡
 GU gastric ulceration§
 DU duodenal ulceration
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diagnostic tests have also been shown to be less
sensitive than non–biopsy-based methods.30
Drugs such as proton pump inhibitors, which are
commonly used to treat bleeding peptic ulcers, can
inhibit the activity of H pylori and can thus hinder the
diagnosis of infection. Simethicone (activated dimethi-
cone), which is commonly used during endoscopic
examinations to reduce the formation of air-bubbles, does
not affect the sensitivity of the RUT despite the in vitro
activity of this drug against H pylori.31
Long-term outcome for patients with
bleeding peptic ulcers
Although most patients with bleeding peptic ulcers
recover from the acute bleeding episode, a significant
proportion of patients experience a subsequent episode
of bleeding. Approximately 30% of patients with
bleeding duodenal ulcers and 20% of patients with
bleeding gastric ulcers have repeat bleeding in the
2 to 3 years after the first episode.32,33
H pylori eradication and bleeding peptic
ulcers that are not associated with the use of
non-steroidal anti-inflammatory drugs
Before the recognition of the role of H pylori in the
pathogenesis of peptic ulcer disease, maintenance
therapy with H2-receptor antagonists was frequently
used to prevent recurrent haemorrhage. In a recent
placebo-controlled trial, ranitidine was found to
significantly reduce the rebleeding rate in instances
of bleeding duodenal ulcers.33 Only 9% of patients
receiving ranitidine maintenance therapy had a
recurrence of bleeding compared with 36% (12/33)
of patients given placebo (mean follow-up period, 61
weeks). However, the disadvantages of such long-
term medical therapy include the high cost and the
problem of gaining long-term patient compliance. Fur-
thermore, up to 10% of patients still had a recurrence
of bleeding despite the long-term maintenance
therapy with H2-receptor antagonists.33
The eradication of H pylori in patients with uncom-
plicated peptic ulcers results in ulcer recurrence rates
of 0% to 10%.8-11 Although there is no convincing
evidence to suggest that bleeding ulcers are inherently
different from non-bleeding ulcers, the role of H pylori
eradication in the management of bleeding peptic
ulcers has been evaluated in a number of studies
(Table 1).34-37 These randomised and non-randomised
studies show unequivocally that the eradication of
H pylori reduces both the recurrence of ulcers and
rebleeding. However, most of these studies had a
follow-up time of only 1 year. In a prospective follow-
up study of 90 consecutive patients with bleeding
gastric ulcers, the cumulative recurrence rate after
2, 5, and 8 years was shown to be 10%, 19%, and 33%,
respectively.32,33 Recently, one randomised study and
one non-randomised study, in which the follow-up was
longer than 4 years, have shown that patients without
H pylori infection rebleed less often than those with
persistent H pylori infection.38,39
Two randomised studies that compared the efficacy
of H pylori eradication with maintenance H2-receptor
antagonist therapy in preventing the recurrence of bleed-
ing peptic ulcers, found that H pylori eradication was
more effective (Table 2).40,41 Hence, it seems that, as
with uncomplicated peptic ulcers, H pylori plays a
major aetiological role in the development of bleed-
ing peptic ulcers. It has been estimated that only
three to four patients need to be treated for H pylori
infection to prevent one duodenal ulcer rebleeding.42
H pylori eradication and bleeding peptic
ulcers in users of non-steroidal anti-
inflammatory drugs
Although the eradication of H pylori substantially
reduces the rate of recurrence of peptic ulceration
No. of patients Rebleeding* Rebleeding† P value
Eradication therapy? Eradication therapy? H pylori present?
Yes No Yes No Yes No
17 14 0/17 4/14 - - <0.05
66 0 - - 0/42 9/24 <0.05
29 22 0/29 6/22 - - <0.05
16 15 0/16 6/15 - - <0.05
60 60 - - 2/41 16/55 <0.05
32 0 - - 0/21 9/11 <0.05
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among patients not taking NSAIDs, eradication
treatment fails to prevent the development of new
peptic ulcers43 and the recurrence of uncomplicated
peptic ulcers among patients using continuous therapy
of NSAIDs.44,45 In contrast, a study has shown that
the eradication of H pylori reduces the development
of peptic ulcers in subjects who are about to start a
course of NSAIDs.46 In this study, 26% of patients with
persistent H pylori infection developed ulcers after
starting NSAID treatment, compared with only 3% of
patients in whom the organism had been successfully
eliminated.46 These findings suggest that H pylori
eradication therapy may be more beneficial for patients
who are not previous NSAID users and are about to
start NSAID treatment.
Only one published study has specifically investi-
gated the effect of eradicating H pylori in patients
with bleeding peptic ulcers.47 Helicobacter pylori
eradication was found to be ineffective compared with
omeprazole treatment in preventing recurrent ulcer
bleeding. Only 2% (1/46) of patients who received
omeprazole maintenance therapy rebled, whereas 20%
(8/41) of patients who received anti–H pylori therapy
rebled.47 It seems likely that NSAID use is more
important than H pylori infection as a risk factor for
the development of mucosal injury and ulceration.
Management of bleeding peptic ulcers that
are not associated with the use of non-
steroidal anti-inflammatory drugs
The prevalence of H pylori is lower in patients with
bleeding peptic ulcers than in those with uncompli-
cated peptic ulcers; hence, it is important to test for
the presence of H pylori before eradication therapy is
started in these patients. It is unsafe to treat all non-
users of NSAIDs who have bleeding peptic ulcers with
anti–H pylori therapy and then to stop all preventive
treatment afterwards, because those without H pylori
infection will have a high risk of rebleeding if long-
term antisecretory treatment is not maintained.
The RUT (eg the CLO [Campylobacter-like
organism] test; Delta West Pty. Ltd., Bentley, Australia)
is most often used to detect H pylori at the time of
endoscopy because of its short detection time. How-
ever, because of the reduced sesitivity of the RUT
when the sample is from a bleeding peptic ulcer,
other tests such as histological examination or the urea
breath test may be required to document the presence
of the bacterium. Patients with confirmed H pylori
infection should receive eradication therapy, whereas
patients without infection would probably require
maintenance therapy with H2-receptor antagonists
(full-dose rather than half-dose may be required) to
reduce the risk of rebleeding.33,48
For H pylori–related bleeding peptic ulcers, thera-
pies with very high eradication rates (>90%) are
generally preferred because failed eradication (and
reinfection) accounts for most cases of rebleeding.35,38,39
Treatment usually includes 1 week of triple therapy
with a proton pump inhibitor, clarithromycin, and either
metronidazole or amoxycillin. Although no clinical
studies have assessed whether 1 to 2 weeks’ eradica-
tion therapy is sufficient for bleeding peptic ulcers,
it is reasonable to continue treatment with an ulcer-
healing drug such as an H2-antagonist for a further 4
to 6 weeks after the bacterium has been eliminated.
This regimen will allow the complete healing of the
complicated ulcer before the H pylori status can be
reassessed. In one study, more than 10% of patients
who had received 1 week of H pylori-eradicating
drugs (bismuth-based triple therapy with ranitidine)
had unhealed ulcers after 6 weeks without an ulcer-
healing drug.41 Maintenance therapy with proton pump
inhibitors or sucralfate should not be given, however,
since these drugs can suppress  H pylori activity and
consequently give false negative results.
The elimination of H pylori should be confirmed
after treatment because the risk of rebleeding remains
high in patients who fail treatment. For those with a
bleeding gastric ulcer, it is recommended that endos-
copy should be performed at least 4 weeks after eradi-
cation therapy to confirm the successful elimination
of H pylori and to exclude the presence of a malignant
tumour in cases of an unhealed gastric ulcer. For those
with duodenal ulcer bleeding, H pylori eradication can
Table 2. H pylori therapy and rebleeding: eradication therapy versus long-term maintenance therapy
Study Study Length of Ulcer No. of No. of patients with rebleeding P value
design follow-up type patients Eradication Long-term
(months) therapy maintenance
Riemann et al,40 1997 Randomised 24 GU*/DU† 95 2/47 4/48 ns
Sung et al,41 1997 Randomised 12 GU/DU 247 0/126 3/121 ns
* GU gastric ulceration†
 DU duodenal ulceration
ns not significant
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be confirmed using non-invasive methods such as the
urea breath test, which is simpler and less expensive
than endoscopic confirmation. Once H pylori eradica-
tion is confirmed, it seems justified, given the signifi-
cantly reduced rebleeding rate post-treatment, that
maintenance antisecretory drugs can be discontinued
(Table 1). A recent study has confirmed that main-
tenance antisecretory treatment is not necessary after
the eradication of H pylori.49 In contrast, long-term
therapy with H2-receptor antagonists should be given
to patients who fail eradication treatment. This meas-
ure may become more important in some regions of
Asia where antibiotic resistance to H pylori is increas-
ing. Since reinfection also accounts for a significant
proportion of rebleeding, maintenance therapy may be
considered for patients in areas where reinfection is
common; further studies, however, are required.
Managing bleeding peptic ulcers in users of
non-steroidal anti-inflammatory drugs
The best intervention for users of NSAIDs who have
a bleeding peptic ulcer is to avoid taking NSAIDs. If
a patient has a concomitant H pylori infection, anti-
H pylori therapy should be attempted, since it is not
possible to determine whether the ulcer is caused
primarily by the NSAIDs or by the infection. If
H pylori is the primary cause, rebleeding would still
occur after the discontinuation of NSAID treatment.
If patients with bleeding ulcers must continue us-
ing NSAIDs, the lowest possible dose of NSAIDs and
the least gastrotoxic NSAIDs such as ibuprofen should
be used.50 Prophylactic therapy with either misoprostol
or omeprazole should also be given if the use of
NSAIDs is continued. Misoprostol has been shown to
reduce the development of new peptic ulcers in pa-
tients taking NSAIDs51; serious ulcer complications
have also been shown to be reduced significantly by
this drug, although the decreased risk for ulcer bleed-
ing was not statistically significant.25 Recently,
omeprazole has been found to be effective in prevent-
ing peptic ulcer recurrence caused by NSAIDs.52-54 For
reasons mentioned above, patients with concomitant
H pylori infection should be given eradication therapy,
although some studies have demonstrated that elimin-
ating the organism does not prevent ulcer recurrence
or bleeding complications.43-45
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